Rosenberg N, Landau M, Luboshitz J, Rechavi G, Seligsohn U
Amalia Biron Research Institute of Thrombosis and Hemostasis, Safra Children's Hospital, The Chaim Sheba Medical Center, Tel-Hashomer, Israel.
J Thromb Haemost. 2004 Jul;2(7):1167-75. doi: 10.1111/j.1538-7836.2004.00758.x.
Glanzmann thrombasthenia (GT) is an autosomal recessive bleeding disorder characterized by lack of platelet aggregation induced by most agonists. The disease is caused by mutations in either alpha(IIb)[glycoprotein (GP) IIb] or beta(3) (GPIIIa) genes that lead to a lack or dysfunction of the integrin alpha(IIb)beta(3) which serves as a fibrinogen receptor.
Mucocutaneous bleeding manifestations and platelet dysfunction consistent with GT were observed in three members of a Cypriot family: a 3-year-old proband, her father and her paternal uncle.
To determine the molecular basis of GT in this family and to characterize possible biochemical and structural defects.
Analysis of the patients' platelets by fluorescence-activated cell sorting demonstrated trace amounts of beta(3), no alpha(IIb) and no alpha(IIb)beta(3) on the membrane. Sequence analysis revealed a novel T607G transversion in exon 5 of the alpha(IIb) gene predicting a Phe171Cys alteration that created a PstI recognition site. All three patients were homozygous for the mutation, the mother and paternal grandparents of the proband were heterozygous, whereas 110 healthy subjects lacked this transversion. Chinese hamster ovary cells cotransfected with cDNAs of mutated alpha(IIb) and wild-type beta(3) failed to express alpha(IIb)beta(3) as shown by immunoprecipitation and immunohistochemistry experiments. Structural analysis of the alpha(IIb)beta(3) model, which was based on the crystal structure of alpha(v)beta(3), indicated that Phe171 plays an essential role in the interface between the beta-propeller domain of alpha(IIb) and the betaA domain of beta(3).
A novel Phe171Cys mutation in the alpha(IIb) gene of patients with GT is associated with abrogation of alpha(IIb)beta(3) complex formation.
Glanzmann血小板无力症(GT)是一种常染色体隐性出血性疾病,其特征为大多数激动剂诱导的血小板聚集缺乏。该疾病由α(IIb)[糖蛋白(GP)IIb]或β(3)(GPIIIa)基因突变引起,这些突变导致作为纤维蛋白原受体的整合素α(IIb)β(3)缺乏或功能障碍。
在一个塞浦路斯家族的三名成员中观察到与GT一致的皮肤黏膜出血表现和血小板功能障碍:一名3岁的先证者、她的父亲和她的叔祖父。
确定该家族中GT的分子基础,并描述可能的生化和结构缺陷。
通过荧光激活细胞分选分析患者血小板,结果显示膜上有微量β(3),无α(IIb)且无α(IIb)β(3)。序列分析显示α(IIb)基因第5外显子有一个新的T607G颠换,预测会出现Phe171Cys改变,产生一个PstI识别位点。所有三名患者均为该突变的纯合子,先证者的母亲和祖父母为杂合子,而110名健康受试者无此颠换。如免疫沉淀和免疫组织化学实验所示,用突变型α(IIb)和野生型β(3)的cDNA共转染的中国仓鼠卵巢细胞未能表达α(IIb)β(3)。基于α(v)β(3)晶体结构的α(IIb)β(3)模型的结构分析表明,Phe171在α(IIb)的β-螺旋桨结构域与β(3)的βA结构域之间的界面中起关键作用。
GT患者α(IIb)基因中的一种新的Phe171Cys突变与α(IIb)β(3)复合物形成的废除有关。